C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

Biotechnology • Healthcare • Watertown, MA, United States • CCCC (NMS)

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

617 231 0700 490 Arsenal Way, Watertown, MA 02472, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Why C4 Therapeutics Stock Crushed the Market on Monday - The Motley Fool
The Motley Fool • Sep 15
With 43% stake, C4 Therapeutics, Inc. (NASDAQ:CCCC) seems to have captured institutional investors' interest - Yahoo Finance
Yahoo Finance • Dec 30
Brookline Capital Management Estimates C4 Therapeutics FY2030 Earnings - MarketBeat
MarketBeat • Jan 6
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - Investing News Network
Investing News Network • Oct 16
Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price - simplywall.st
simplywall.st • Dec 17

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has C4 Therapeutics, Inc. had layoffs?
No layoff events have been recorded for C4 Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does C4 Therapeutics, Inc. have?
C4 Therapeutics, Inc. has approximately 110 employees.
What industry is C4 Therapeutics, Inc. in?
C4 Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is C4 Therapeutics, Inc. a publicly traded company?
Yes, C4 Therapeutics, Inc. is publicly traded under the ticker symbol CCCC on the NMS. The company has a market capitalization of approximately $0.21 billion.
Where is C4 Therapeutics, Inc. headquartered?
C4 Therapeutics, Inc. is headquartered in Watertown, MA, United States at 490 Arsenal Way, Watertown, MA 02472, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.